• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于透明质酸的肝素结合体外循环回路在不同风险队列中的临床性能和生物相容性。

Clinical performance and biocompatibility of hyaluronan-based heparin-bonded extracorporeal circuits in different risk cohorts.

作者信息

Gunaydin Serdar, McCusker Kevin, Sari Tamer, Onur Mehmet Ali, Zorlutuna Yaman

机构信息

University of Kirikkale, Angora Evleri G-8 Bl. No: 1, Ankara, Turkey.

出版信息

Interact Cardiovasc Thorac Surg. 2010 Mar;10(3):371-6. doi: 10.1510/icvts.2009.220756. Epub 2009 Dec 21.

DOI:10.1510/icvts.2009.220756
PMID:20026488
Abstract

This prospective randomized study compares novel hyaluronan-based heparin-bonded circuits vs. uncoated controls across EuroSCORE patient risk strata including biomaterial evaluation. Over a two-year period, 90 patients undergoing coronary artery bypass grafting were prospectively randomized to one of the two perfusion protocols: Group 1 was treated with hyaluronan-based heparin-bonded preconnected circuits (Vision HFO-GBS, Gish, CA, USA) and Group 2 with identical uncoated controls. Each group was composed of three subgroups (n=15) with respect to preoperative evaluation of low (EuroSCORE 0-2), medium (3-5) and high (6+) risk patients. Blood samples were collected after induction (T1) and heparinization (T2), 15 min after cardiopulmonary bypass start (T3), before cessation of CPB (T4), 15 min after reversal (T5), and the first postoperative day (T6). In high-risk patients, platelet counts demonstrated significant preservation at T4, T5 and leukocyte counts were lower at T5 in hyaluronan group (P<or=0.05 vs. control). C3a (ng x ml(-1)) levels were significantly lower at T3 (0.2+/-0.04 vs. 0.31+/-0.05), T4 (0.25+/-0.04 vs. 0.51+/-0.05), T5 (0.38+/-0.04 vs. 0.56+/-0.05) and interleukin-6 (pg x ml(-1)) at T4 (91+/-18 vs. 124+/-20), T5 (110+/-20 vs. 220+/-25) in coated group vs. control (P<or=0.05). Protein desorption (microalbumin) on fibers (mg x mm(-3)) was less in hyaluronan vs. control groups (P<or=0.05). Hyaluronan coating reduced platelet adhesion and cell adsorption, and modulated inflammatory response in high-risk patients.

摘要

这项前瞻性随机研究比较了新型基于透明质酸的肝素结合回路与未涂层对照在欧洲心脏手术风险评估系统(EuroSCORE)患者风险分层中的效果,包括生物材料评估。在两年时间里,90例接受冠状动脉旁路移植术的患者被前瞻性随机分为两种灌注方案之一:第1组接受基于透明质酸的肝素结合预连接回路(Vision HFO - GBS,Gish,加利福尼亚州,美国)治疗,第2组接受相同的未涂层对照。根据术前评估的低(EuroSCORE 0 - 2)、中(3 - 5)和高(6+)风险患者,每组又分为三个亚组(n = 15)。在诱导后(T1)和肝素化后(T2)、体外循环开始后15分钟(T3)、体外循环停止前(T4)、肝素逆转后15分钟(T5)以及术后第一天(T6)采集血样。在高危患者中,透明质酸组在T4时血小板计数显示出显著的保存,在T5时白细胞计数较低(与对照组相比,P≤0.05)。涂层组在T3(0.2±0.04对0.31±0.05)、T4(0.25±0.04对0.51±0.05)、T5(0.38±0.04对0.56±0.05)时C3a(ng·ml⁻¹)水平显著较低,在T4(91±18对124±20)、T5(110±20对220±25)时白细胞介素-6(pg·ml⁻¹)水平显著低于对照组(P≤0.05)。与对照组相比,透明质酸组纤维上的蛋白质解吸(微量白蛋白)(mg·mm⁻³)较少(P≤0.05)。透明质酸涂层减少了高危患者的血小板黏附和细胞吸附,并调节了炎症反应。

相似文献

1
Clinical performance and biocompatibility of hyaluronan-based heparin-bonded extracorporeal circuits in different risk cohorts.基于透明质酸的肝素结合体外循环回路在不同风险队列中的临床性能和生物相容性。
Interact Cardiovasc Thorac Surg. 2010 Mar;10(3):371-6. doi: 10.1510/icvts.2009.220756. Epub 2009 Dec 21.
2
Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.在冠状动脉血运重建再次手术中,对基于透明质酸的肝素结合体外循环进行临床和生物材料评估,比较减少全身抗凝与完全全身抗凝的效果。
J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):135-42. doi: 10.2459/JCM.0b013e32831eef9d.
3
Comparison of polymethoxyethylacrylate-coated circuits with leukocyte filtration and reduced heparinization protocol on heparin-bonded circuits in different risk cohorts.不同风险队列中,聚甲氧基乙基丙烯酸酯涂层回路联合白细胞滤过及减少肝素化方案与肝素结合回路的比较。
Perfusion. 2006 Nov;21(6):329-42. doi: 10.1177/0267659106070507.
4
Clinical performance and biocompatibility of novel hyaluronan-based heparin-bonded extracorporeal circuits.新型透明质酸基肝素结合体外循环装置的临床性能和生物相容性
J Extra Corpor Technol. 2005 Sep;37(3):290-5.
5
Clinical evaluation of minimized extracorporeal circulation in high-risk coronary revascularization: impact on air handling, inflammation, hemodilution and myocardial function.高危冠状动脉血运重建中体外循环最小化的临床评估:对空气处理、炎症、血液稀释及心肌功能的影响
Perfusion. 2009 May;24(3):153-62. doi: 10.1177/0267659109346664. Epub 2009 Sep 15.
6
Clinical and biomaterial evaluation of a new condensed dual-function extracorporeal circuit in reoperation for coronary artery bypass surgery.新型浓缩双功能体外循环装置在冠状动脉搭桥手术再次手术中的临床及生物材料评估
Int J Artif Organs. 2009 Nov;32(11):802-10. doi: 10.1177/039139880903201106.
7
Clinical efficacy of leukofiltration on cardiopulmonary bypass related inflammatory response: Fact or Foe?白细胞滤过对体外循环相关炎症反应的临床疗效:利还是弊?
Inflamm Res. 2009 Jun;58(6):292-7. doi: 10.1007/s00011-008-7244-1.
8
The impact of allogenic red cell transfusion and coated bypass circuit on the inflammatory response during cardiopulmonary bypass: a randomized study.异体红细胞输注和涂层体外循环回路对体外循环期间炎症反应的影响:一项随机研究。
Interact Cardiovasc Thorac Surg. 2009 Jan;8(1):93-9. doi: 10.1510/icvts.2008.183608. Epub 2008 Sep 18.
9
Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.肝素涂层体外循环回路在左心室功能不全的冠心病患者中的生物相容性优于聚甲基丙烯酸甲酯涂层回路。
J Card Surg. 2006 Nov-Dec;21(6):572-7. doi: 10.1111/j.1540-8191.2006.00298.x.
10
Inflammatory response after coronary revascularization: off-pump versus on-pump (heparin-coated circuits and poly2methoxyethylacrylate-coated circuits).冠状动脉血运重建后的炎症反应:非体外循环与体外循环(肝素涂层回路和聚2-甲氧基乙基丙烯酸酯涂层回路)。
Ann Thorac Cardiovasc Surg. 2004 Apr;10(2):90-6.

引用本文的文献

1
Strategies to attenuate maladaptive inflammatory response associated with cardiopulmonary bypass.减轻与体外循环相关的适应性炎症反应的策略。
Front Surg. 2024 Jul 3;11:1224068. doi: 10.3389/fsurg.2024.1224068. eCollection 2024.
2
Microfluidic cell sorting: Towards improved biocompatibility of extracorporeal lung assist devices.微流控细胞分选:提高体外肺辅助设备生物相容性的方法。
Sci Rep. 2018 May 23;8(1):8031. doi: 10.1038/s41598-018-25977-6.
3
VV extracorporeal life support for the Third Millennium: will we need anticoagulation?
面向第三个千年的静脉-静脉体外生命支持:我们需要抗凝吗?
J Thorac Dis. 2018 Mar;10(Suppl 5):S698-S706. doi: 10.21037/jtd.2017.11.89.
4
Effects of cardiopulmonary bypass on lung nuclear factor-kappa B activity, cytokine release, and pulmonary function in dogs.体外循环对犬肺核因子-κB活性、细胞因子释放及肺功能的影响。
Iran J Basic Med Sci. 2015 Dec;18(12):1233-9.
5
Cardiopulmonary Bypass, Inflammation and How to Defy it: Focus on Pharmacological Interventions.体外循环、炎症及如何对抗炎症:聚焦于药物干预措施
Iran J Pharm Res. 2012 Summer;11(3):705-14.
6
Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit?全肝素化体外循环回路是否优于标准体外循环回路?
Interact Cardiovasc Thorac Surg. 2012 Apr;14(4):406-14. doi: 10.1093/icvts/ivr124. Epub 2012 Jan 6.
7
Hyaluronan based heparin free coated open and closed extracorporeal circuits for high risk coronary revascularization.用于高风险冠状动脉血运重建的基于透明质酸的无肝素涂层开放和闭合体外循环回路
J Extra Corpor Technol. 2010 Dec;42(4):286-92.